346 related articles for article (PubMed ID: 7689950)
1. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
Clapp C; Martial JA; Guzman RC; Rentier-Delure F; Weiner RI
Endocrinology; 1993 Sep; 133(3):1292-9. PubMed ID: 7689950
[TBL] [Abstract][Full Text] [Related]
2. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells.
Ferrara N; Clapp C; Weiner R
Endocrinology; 1991 Aug; 129(2):896-900. PubMed ID: 1855480
[TBL] [Abstract][Full Text] [Related]
3. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.
Martini JF; Piot C; Humeau LM; Struman I; Martial JA; Weiner RI
Mol Endocrinol; 2000 Oct; 14(10):1536-49. PubMed ID: 11043570
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance.
Piwnica D; Touraine P; Struman I; Tabruyn S; Bolbach G; Clapp C; Martial JA; Kelly PA; Goffin V
Mol Endocrinol; 2004 Oct; 18(10):2522-42. PubMed ID: 15192082
[TBL] [Abstract][Full Text] [Related]
5. A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.
Clapp C; Weiner RI
Endocrinology; 1992 Mar; 130(3):1380-6. PubMed ID: 1311239
[TBL] [Abstract][Full Text] [Related]
6. 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.
D'Angelo G; Martini JF; Iiri T; Fantl WJ; Martial J; Weiner RI
Mol Endocrinol; 1999 May; 13(5):692-704. PubMed ID: 10319320
[TBL] [Abstract][Full Text] [Related]
7. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.
Bentzien F; Struman I; Martini JF; Martial J; Weiner R
Cancer Res; 2001 Oct; 61(19):7356-62. PubMed ID: 11585777
[TBL] [Abstract][Full Text] [Related]
8. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation.
Gonzalez C; Corbacho AM; Eiserich JP; Garcia C; Lopez-Barrera F; Morales-Tlalpan V; Barajas-Espinosa A; Diaz-Muñoz M; Rubio R; Lin SH; Martinez de la Escalera G; Clapp C
Endocrinology; 2004 Dec; 145(12):5714-22. PubMed ID: 15358675
[TBL] [Abstract][Full Text] [Related]
9. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin.
Khurana S; Liby K; Buckley AR; Ben-Jonathan N
Endocrinology; 1999 Sep; 140(9):4127-32. PubMed ID: 10465285
[TBL] [Abstract][Full Text] [Related]
11. The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells.
Kinet V; Castermans K; Herkenne S; Maillard C; Blacher S; Lion M; Noël A; Martial JA; Struman I
Endocrinology; 2011 Nov; 152(11):4062-71. PubMed ID: 21862622
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.
Lee H; Struman I; Clapp C; Martial J; Weiner RI
Endocrinology; 1998 Sep; 139(9):3696-703. PubMed ID: 9724020
[TBL] [Abstract][Full Text] [Related]
13. The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.
Nguyen NQ; Castermans K; Berndt S; Herkenne S; Tabruyn SP; Blacher S; Lion M; Noel A; Martial JA; Struman I
PLoS One; 2011; 6(11):e27318. PubMed ID: 22087289
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice.
Pan H; Nguyen NQ; Yoshida H; Bentzien F; Shaw LC; Rentier-Delrue F; Martial JA; Weiner R; Struman I; Grant MB
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2413-9. PubMed ID: 15223825
[TBL] [Abstract][Full Text] [Related]
15. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth.
Rhim TY; Park CS; Kim E; Kim SS
Biochem Biophys Res Commun; 1998 Nov; 252(2):513-6. PubMed ID: 9826562
[TBL] [Abstract][Full Text] [Related]
16. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.
Tabruyn SP; Sabatel C; Nguyen NQ; Verhaeghe C; Castermans K; Malvaux L; Griffioen AW; Martial JA; Struman I
Mol Endocrinol; 2007 Jun; 21(6):1422-9. PubMed ID: 17405903
[TBL] [Abstract][Full Text] [Related]
17. Biological and immunological characterization of cleaved and 16K forms of rat prolactin.
Clapp C; Sears PS; Russell DH; Richards J; Levay-Young BK; Nicoll CS
Endocrinology; 1988 Jun; 122(6):2892-8. PubMed ID: 3371265
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.
Anand-Apte B; Pepper MS; Voest E; Montesano R; Olsen B; Murphy G; Apte SS; Zetter B
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):817-23. PubMed ID: 9112976
[TBL] [Abstract][Full Text] [Related]
19. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.
Tabruyn SP; Nguyen NQ; Cornet AM; Martial JA; Struman I
Mol Endocrinol; 2005 Jul; 19(7):1932-42. PubMed ID: 15746189
[TBL] [Abstract][Full Text] [Related]
20. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
